Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab
Background: Validated predictors of sensitivity or resistance to Bevacizumab (Bev) are not available, and Inflammatory Indexes (IIs) has been reported to be useful prognostic factors in various malignant solid tumours, including metastatic colorectal cancer (mCRC). Objectives: To explore the prognos...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-12-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359231212184 |
| _version_ | 1827584542081286144 |
|---|---|
| author | Alessandro Passardi Irene Azzali Alessandro Bittoni Giorgia Marisi Francesca Rebuzzi Chiara Molinari Giulia Bartolini Laura Matteucci Francesco Giulio Sullo Silvia Angela Debonis Chiara Gallio Manlio Monti Martina Valgiusti Margherita Muratore Ilario Giovanni Rapposelli Paola Ulivi Giovanni Luca Frassineti |
| author_facet | Alessandro Passardi Irene Azzali Alessandro Bittoni Giorgia Marisi Francesca Rebuzzi Chiara Molinari Giulia Bartolini Laura Matteucci Francesco Giulio Sullo Silvia Angela Debonis Chiara Gallio Manlio Monti Martina Valgiusti Margherita Muratore Ilario Giovanni Rapposelli Paola Ulivi Giovanni Luca Frassineti |
| author_sort | Alessandro Passardi |
| collection | DOAJ |
| description | Background: Validated predictors of sensitivity or resistance to Bevacizumab (Bev) are not available, and Inflammatory Indexes (IIs) has been reported to be useful prognostic factors in various malignant solid tumours, including metastatic colorectal cancer (mCRC). Objectives: To explore the prognostic value of IIs in mCRC patients treated with first-line chemotherapy plus Bev. Design: One hundred and eighty-two patients diagnosed with mCRC and treated with first line chemotherapy plus Bev were considered for this prospective non-pharmacological study. Neutrophil, lymphocyte, platelet, aspartate transaminase (AST) and lactate dehydrogenase (LDH) tests were carried out at baseline and before each treatment cycle, according to clinical practice. Methods: Pre-treatment Systemic Immune-inflammation Index (SII), Colon Inflammatory Index (CII) and Aspartate aminotransferase-Lymphocyte Ratio Index (ALRI) were evaluated to assess a correlation with progression-free survival (PFS) and overall survival (OS). Results: In the overall population, PFS and OS were lower in patients with high SII (HR 1.64, p = 0.006 and HR 1.75, p = 0.004, respectively) and high ALRI (HR 2.13, p = 0.001 and HR 1.76, p = 0.02, respectively), but no difference was detected according to CII value. The multivariate analysis confirmed both SII and ALRI as independent prognostic factors for PFS (HR 1.64 and 2.82, respectively) and OS (HR 1.65 and 2.12, respectively). Conclusion: Our results demonstrate and confirm that IIs, and in particular SII and ALRI, are easy to measure prognostic markers for patient candidates to first line chemotherapy plus Bev for mCRC. |
| first_indexed | 2024-03-08T23:31:49Z |
| format | Article |
| id | doaj.art-7c76b2cc5c08402fb671d3dfe99c2c81 |
| institution | Directory Open Access Journal |
| issn | 1758-8359 |
| language | English |
| last_indexed | 2024-03-08T23:31:49Z |
| publishDate | 2023-12-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj.art-7c76b2cc5c08402fb671d3dfe99c2c812023-12-14T13:06:17ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592023-12-011510.1177/17588359231212184Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus BevacizumabAlessandro PassardiIrene AzzaliAlessandro BittoniGiorgia MarisiFrancesca RebuzziChiara MolinariGiulia BartoliniLaura MatteucciFrancesco Giulio SulloSilvia Angela DebonisChiara GallioManlio MontiMartina ValgiustiMargherita MuratoreIlario Giovanni RapposelliPaola UliviGiovanni Luca FrassinetiBackground: Validated predictors of sensitivity or resistance to Bevacizumab (Bev) are not available, and Inflammatory Indexes (IIs) has been reported to be useful prognostic factors in various malignant solid tumours, including metastatic colorectal cancer (mCRC). Objectives: To explore the prognostic value of IIs in mCRC patients treated with first-line chemotherapy plus Bev. Design: One hundred and eighty-two patients diagnosed with mCRC and treated with first line chemotherapy plus Bev were considered for this prospective non-pharmacological study. Neutrophil, lymphocyte, platelet, aspartate transaminase (AST) and lactate dehydrogenase (LDH) tests were carried out at baseline and before each treatment cycle, according to clinical practice. Methods: Pre-treatment Systemic Immune-inflammation Index (SII), Colon Inflammatory Index (CII) and Aspartate aminotransferase-Lymphocyte Ratio Index (ALRI) were evaluated to assess a correlation with progression-free survival (PFS) and overall survival (OS). Results: In the overall population, PFS and OS were lower in patients with high SII (HR 1.64, p = 0.006 and HR 1.75, p = 0.004, respectively) and high ALRI (HR 2.13, p = 0.001 and HR 1.76, p = 0.02, respectively), but no difference was detected according to CII value. The multivariate analysis confirmed both SII and ALRI as independent prognostic factors for PFS (HR 1.64 and 2.82, respectively) and OS (HR 1.65 and 2.12, respectively). Conclusion: Our results demonstrate and confirm that IIs, and in particular SII and ALRI, are easy to measure prognostic markers for patient candidates to first line chemotherapy plus Bev for mCRC.https://doi.org/10.1177/17588359231212184 |
| spellingShingle | Alessandro Passardi Irene Azzali Alessandro Bittoni Giorgia Marisi Francesca Rebuzzi Chiara Molinari Giulia Bartolini Laura Matteucci Francesco Giulio Sullo Silvia Angela Debonis Chiara Gallio Manlio Monti Martina Valgiusti Margherita Muratore Ilario Giovanni Rapposelli Paola Ulivi Giovanni Luca Frassineti Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab Therapeutic Advances in Medical Oncology |
| title | Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab |
| title_full | Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab |
| title_fullStr | Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab |
| title_full_unstemmed | Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab |
| title_short | Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab |
| title_sort | inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus bevacizumab |
| url | https://doi.org/10.1177/17588359231212184 |
| work_keys_str_mv | AT alessandropassardi inflammatoryindicesasprognosticmarkersinmetastaticcolorectalcancerpatientstreatedwithchemotherapyplusbevacizumab AT ireneazzali inflammatoryindicesasprognosticmarkersinmetastaticcolorectalcancerpatientstreatedwithchemotherapyplusbevacizumab AT alessandrobittoni inflammatoryindicesasprognosticmarkersinmetastaticcolorectalcancerpatientstreatedwithchemotherapyplusbevacizumab AT giorgiamarisi inflammatoryindicesasprognosticmarkersinmetastaticcolorectalcancerpatientstreatedwithchemotherapyplusbevacizumab AT francescarebuzzi inflammatoryindicesasprognosticmarkersinmetastaticcolorectalcancerpatientstreatedwithchemotherapyplusbevacizumab AT chiaramolinari inflammatoryindicesasprognosticmarkersinmetastaticcolorectalcancerpatientstreatedwithchemotherapyplusbevacizumab AT giuliabartolini inflammatoryindicesasprognosticmarkersinmetastaticcolorectalcancerpatientstreatedwithchemotherapyplusbevacizumab AT lauramatteucci inflammatoryindicesasprognosticmarkersinmetastaticcolorectalcancerpatientstreatedwithchemotherapyplusbevacizumab AT francescogiuliosullo inflammatoryindicesasprognosticmarkersinmetastaticcolorectalcancerpatientstreatedwithchemotherapyplusbevacizumab AT silviaangeladebonis inflammatoryindicesasprognosticmarkersinmetastaticcolorectalcancerpatientstreatedwithchemotherapyplusbevacizumab AT chiaragallio inflammatoryindicesasprognosticmarkersinmetastaticcolorectalcancerpatientstreatedwithchemotherapyplusbevacizumab AT manliomonti inflammatoryindicesasprognosticmarkersinmetastaticcolorectalcancerpatientstreatedwithchemotherapyplusbevacizumab AT martinavalgiusti inflammatoryindicesasprognosticmarkersinmetastaticcolorectalcancerpatientstreatedwithchemotherapyplusbevacizumab AT margheritamuratore inflammatoryindicesasprognosticmarkersinmetastaticcolorectalcancerpatientstreatedwithchemotherapyplusbevacizumab AT ilariogiovannirapposelli inflammatoryindicesasprognosticmarkersinmetastaticcolorectalcancerpatientstreatedwithchemotherapyplusbevacizumab AT paolaulivi inflammatoryindicesasprognosticmarkersinmetastaticcolorectalcancerpatientstreatedwithchemotherapyplusbevacizumab AT giovannilucafrassineti inflammatoryindicesasprognosticmarkersinmetastaticcolorectalcancerpatientstreatedwithchemotherapyplusbevacizumab |